Cargando…

c-Met as a Target for Personalized Therapy

MET and its ligand HGF are involved in many biological processes, both physiological and pathological, making this signaling pathway an attractive therapeutic target in oncology. Downstream signaling effects are transmitted via mitogen-activated protein kinase (MAPK), PI3K (phosphoinositide 3-kinase...

Descripción completa

Detalles Bibliográficos
Autores principales:	Garajová, Ingrid, Giovannetti, Elisa, Biasco, Guido, Peters, Godefridus J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Libertas Academica 2015
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4659440/ https://www.ncbi.nlm.nih.gov/pubmed/26628860 http://dx.doi.org/10.4137/TOG.S30534

Ejemplares similares

Role of Akt signaling in resistance to DNA-targeted therapy
por: Avan, Abolfazl, et al.
Publicado: (2016)

Comment on: Targeting the HGF/c-MET pathway in advanced pancreatic cancer: a key element of treatment that limits primary tumour growth and eliminates metastasis
por: Che, Pei Pei, et al.
Publicado: (2020)

MicroRNA profiling of primary pulmonary enteric adenocarcinoma in members from the same family reveals some similarities to pancreatic adenocarcinoma—a step towards personalized therapy
por: Garajová, Ingrid, et al.
Publicado: (2015)

USP1 deubiquitinase: cellular functions, regulatory mechanisms and emerging potential as target in cancer therapy
por: García-Santisteban, Iraia, et al.
Publicado: (2013)

Non-Coding RNAs as Predictive Biomarkers to Current Treatment in Metastatic Colorectal Cancer
por: Garajová, Ingrid, et al.
Publicado: (2017)

Pharmacokinetics and pharmacogenetics of Gemcitabine as a mainstay in adult and pediatric oncology: an EORTC-PAMM perspective
por: Ciccolini, Joseph, et al.
Publicado: (2016)

Target Therapy in Malignant Pleural Mesothelioma: Hope or Mirage?
por: Borea, Federica, et al.
Publicado: (2023)

Targeting miRNA and using miRNA as potential therapeutic options to bypass resistance in pancreatic ductal adenocarcinoma
por: Vahabi, Mahrou, et al.
Publicado: (2023)

Anaplastic lymphoma kinase inhibition in metastatic non-small cell lung cancer: clinical impact of alectinib
por: Muller, Ittai B, et al.
Publicado: (2017)

“Open Sesame?”: Biomarker Status of the Human Equilibrative Nucleoside Transporter-1 and Molecular Mechanisms Influencing its Expression and Activity in the Uptake and Cytotoxicity of Gemcitabine in Pancreatic Cancer
por: Randazzo, Ornella, et al.
Publicado: (2020)

Neoadjuvant Treatment in Rectal Cancer: Actual Status
por: Garajová, Ingrid, et al.
Publicado: (2011)

Role of c-MET Inhibitors in Overcoming Drug Resistance in Spheroid Models of Primary Human Pancreatic Cancer and Stellate Cells
por: Firuzi, Omidreza, et al.
Publicado: (2019)

Can cytidine deaminase be used as predictive biomarker for gemcitabine toxicity and response?
por: Peters, Godefridus J., et al.
Publicado: (2019)

New developments in the management of non-small-cell lung cancer, focus on rociletinib: what went wrong?
por: Van Der Steen, Nele, et al.
Publicado: (2016)

Potential Role of Exosomes in the Chemoresistance to Gemcitabine and Nab-Paclitaxel in Pancreatic Cancer
por: Comandatore, Annalisa, et al.
Publicado: (2022)

Molecular Mechanisms Underlying the Role of MicroRNAs in the Chemoresistance of Pancreatic Cancer
por: Garajová, Ingrid, et al.
Publicado: (2014)

Targeting MET in Non-Small Cell Lung Cancer (NSCLC): A New Old Story?
por: Spagnolo, Calogera Claudia, et al.
Publicado: (2023)

Cyclin Dependent Kinase-1 (CDK-1) Inhibition as a Novel Therapeutic Strategy against Pancreatic Ductal Adenocarcinoma (PDAC)
por: Wijnen, Rosa, et al.
Publicado: (2021)

Genetic heterogeneity in cholangiocarcinoma: a major challenge for targeted therapies
por: Brandi, Giovanni, et al.
Publicado: (2015)

Fungal mycobiome-mediated immune response: a non-negligible promoter in pancreatic oncogenesis and chemoresistance
por: Jiang, Yaling, et al.
Publicado: (2023)

Development of antibody-based c-Met inhibitors for targeted cancer therapy
por: Lee, Dongheon, et al.
Publicado: (2015)

The Role of c-Met as a Biomarker and Player in Innate and Acquired Resistance in Non-Small-Cell Lung Cancer: Two New Mutations Warrant Further Studies
por: Van Der Steen, Nele, et al.
Publicado: (2019)

Biomarker development in MET-targeted therapy
por: Zhang, Yanni, et al.
Publicado: (2016)

CX-5461 Inhibits Pancreatic Ductal Adenocarcinoma Cell Growth, Migration and Induces DNA Damage
por: El Hassouni, Btissame, et al.
Publicado: (2019)

hENT-1 Expression and Localization Predict Outcome After Adjuvant Gemcitabine in Resected Cholangiocarcinoma Patients
por: Meijer, Laura L., et al.
Publicado: (2016)

MET in glioma: signaling pathways and targeted therapies
por: Cheng, Fangling, et al.
Publicado: (2019)

MET Oncogene in Non-Small Cell Lung Cancer: Mechanism of MET Dysregulation and Agents Targeting the HGF/c-Met Axis
por: Liang, Hongge, et al.
Publicado: (2020)

An Observatory for the MET Oncogene: A Guide for Targeted Therapies
por: Altintas, Dogus M., et al.
Publicado: (2023)

Targeting HGF/c-MET Axis in Pancreatic Cancer
por: Pothula, Srinivasa P., et al.
Publicado: (2020)

c-Met: A Promising Therapeutic Target in Bladder Cancer
por: Feng, Yanfei, et al.
Publicado: (2022)

Interrelationship between miRNA and splicing factors in pancreatic ductal adenocarcinoma
por: Supadmanaba, I Gede Putu, et al.
Publicado: (2021)

Targeting the HGF-cMET Axis in Hepatocellular Carcinoma
por: Venepalli, Neeta K., et al.
Publicado: (2013)

Targeting MET in cancer therapy
por: Mo, Hong-Nan, et al.
Publicado: (2017)

Efficacy of CAR-T immunotherapy in MET overexpressing tumors not eligible for anti-MET targeted therapy
por: Chiriaco, Cristina, et al.
Publicado: (2022)

Pancreatic cancer resistance conferred by stellate cells: looking for new preclinical models
por: Che, Pei Pei, et al.
Publicado: (2020)

Companion Diagnostics and Predictive Biomarkers for MET-Targeted Therapy in NSCLC
por: Jørgensen, Jan Trøst, et al.
Publicado: (2022)

MET Signaling Pathways, Resistance Mechanisms, and Opportunities for Target Therapies
por: Rivas, Solange, et al.
Publicado: (2022)

Better to be alone than in bad company: The antagonistic effect of cisplatin and crizotinib combination therapy in non-small cell lung cancer
por: Van Der Steen, Nele, et al.
Publicado: (2016)

Galectin-4 expression is associated with reduced lymph node metastasis and modulation of Wnt/β-catenin signalling in pancreatic adenocarcinoma
por: Maftouh, Mina, et al.
Publicado: (2014)

Status of Agents Targeting the HGF/c-Met Axis in Lung Cancer
por: Miranda, Oshin, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_o0g5skji4ebn30lrgtegu1q555